ArticleNature communications2022
Post-covid medical complaints following infection with SARS-CoV-2 Omicron vs Delta variants.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.
- Systematic review of post-COVID condition in Nordic population-based registry studies.Nature communications · 2025Pooled it
- Article
- The age paradox in post-infectious sequelae: physiological reserve outweighs chronological age in Long COVID susceptibility.medRxiv : the preprint server for health sciences · 2026Article
- Health outcomes in hospitalised and non-hospitalised individuals after COVID-19, an observational, cross-sectional study.Communications medicine · 2025Article
- Post-COVID-19 condition in individuals infected with SARS-CoV-2 in autumn 2023 in the Netherlands: a prospective cohort study with pre- and post-infection data.The Lancet regional health. Europe · 2025Article
- Prevalence and characterization of post-acute sequelae of SARS-CoV-2 infection (PASC) in Rwanda.IJID regions · 2025Article
- Safety and efficacy of endoscopy-guided nasojejunal feeding tube placement in ICU post-COVID-19 patients: a retrospective study.European journal of medical research · 2025Article
- Long COVID Incidence Proportion in Adults and Children Between 2020 and 2024: An Electronic Health Record-Based Study From the RECOVER Initiative.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Health outcomes one year after Omicron infection among 12,789 adults: a community-based cross-sectional study.The Lancet regional health. Western Pacific · 2025Article
- Review of organ damage from COVID and Long COVID: a disease with a spectrum of pathology.Medical review (2021) · 2025Review
- Long COVID incidence across SARS-CoV-2 lineages and identification of conserved spike targets for multivalent vaccines.Journal of clinical and translational science · 2025Article
- Persistence of Long COVID Symptoms Two Years After SARS-CoV-2 Infection: A Prospective Longitudinal Cohort Study.Viruses · 2024Article
- Observational
- Characteristics and predictors of Long Covid in children: a 3-year prospective cohort study.EClinicalMedicine · 2024Article
- Article
- Impact of Long SARS-CoV-2 Omicron Infection on the Health Care Burden: Comparative Case-Control Study Between Omicron and Pre-Omicron Waves.JMIR public health and surveillance · 2024Article
- Risk of COVID-19 in Children throughout the Pandemic and the Role of Vaccination: A Narrative Review.Vaccines · 2024Review
- Symptoms, Course, and Factors Related to Long-Term Morbidity, Including Differences between Infection Strains, in Patients with Long COVID in a Primary Care Clinic in Japan: An Observational Study.Journal of clinical medicine · 2024Article
- Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia.BMC infectious diseases · 2024Article
- Postacute symptoms 4 months after SARS-CoV-2 infection during the Omicron period: a nationwide Danish questionnaire study.American journal of epidemiology · 2024Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SARS-CoV-2 Omicron (B.1.1.529) variant has been associated with less severe acute disease, however, concerns remain as to whether long-term complaints persist to a similar extent as for earlier variants. Studying 1 323 145 persons aged 18-70 years living in Norway with and without SARS-CoV-2 infection in a prospective cohort study, we found that individuals infected with Omicron had a similar risk of post-covid complaints (fatigue, cough, heart palpitations, shortness of breath and anxiety/depression) as individuals infected with Delta (B.1.617.2), from 14 to up to 126 days after testing positive, both in the acute (14 to 29 days), sub-acute (30 to 89 days) and chronic post-covid (≥90 days) phases. However, at ≥90 days after testing positive, individuals infected with Omicron had a lower risk of having any complaint (43 (95%CI = 14 to 72) fewer per 10,000), as well as a lower risk of musculoskeletal pain (23 (95%CI = 2-43) fewer per 10,000) than individuals infected with Delta. Our findings suggest that the acute and sub-acute burden of post-covid complaints on health services is similar for Omicron and Delta. The chronic burden may be lower for Omicron vs Delta when considering musculoskeletal pain, but not when considering other typical post-covid complaints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.